Chen Yang
Impact in
- Cancer Research top 2%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Cancer, Lipids, and Metabolism
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Circular RNAs in diseases 12
- RNA modifications and cancer 11
- Ubiquitin and proteasome pathways 7
- Oncology 36
- CAR-T cell therapy research 6
- Co-authors
- Xiangmin Tong (13 shared papers)Zhongkai Gu (1 shared paper)Xiaolong Liu (1 shared paper)Wei Chen (1 shared paper)Xiaomo Wu (1 shared paper)Zhi‐Ming Shao (8 shared papers)Yanchun Li (8 shared papers)Yi Zhou (7 shared papers)
- Journals
- Breast Cancer Research and Treatment (8 papers)Cell Death and Disease (5 papers)Cancer Cell International (5 papers)Aging (3 papers)Biomedicine & Pharmacotherapy (3 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Chen Yang
148 papers receiving 3.7k citations
Chen Yang's Hit Papers
Peers
Comparison fields: 5 of 126
- Cancer Research 906
- Oncology 886
- Molecular Biology 1.7k
- Pulmonary and Respiratory Medicine 711
- Immunology 435
Countries citing papers authored by Chen Yang
This map shows the geographic impact of Chen Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chen Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chen Yang more than expected).
Fields of papers citing papers by Chen Yang
This network shows the impact of papers produced by Chen Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chen Yang. The network helps show where Chen Yang may publish in the future.
Co-authors
The 25 scholars most cited alongside Chen Yang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 157 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Application of PD-1 Blockade in Cancer Immunotherapy Hit paper breakdown → | 2019 | 384 |
| 2 | Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis Hit paper breakdown → | 2021 | 236 |
| 3 | 2018 | 198 | |
| 4 | 2021 | 143 | |
| 5 | 2022 | 135 | |
| 6 | 2021 | 108 | |
| 7 | 2022 | 103 | |
| 8 | 2023 | 80 | |
| 9 | 2021 | 80 | |
| 10 | 2011 | 72 | |
| 11 | 2023 | 72 | |
| 12 | 2016 | 61 | |
| 13 | 2017 | 60 | |
| 14 | 2021 | 59 | |
| 15 | 2012 | 59 | |
| 16 | 2023 | 59 | |
| 17 | 2023 | 58 | |
| 18 | 2017 | 50 | |
| 19 | 2011 | 50 | |
| 20 | 2009 | 50 |
About Chen Yang
Chen Yang is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Cancer Research and Genetics, having authored 157 papers that have together received 3.8k indexed citations. Recurring topics across this work include Ferroptosis and cancer prognosis (15 papers), Circular RNAs in diseases (12 papers), MicroRNA in disease regulation (11 papers), RNA modifications and cancer (11 papers), Immunotherapy and Immune Responses (9 papers), Cancer-related molecular mechanisms research (8 papers), Ubiquitin and proteasome pathways (7 papers) and CAR-T cell therapy research (6 papers). The work is most often cited by research in Cancer Research (906 citations), Oncology (886 citations), Molecular Biology (1.7k citations), Pulmonary and Respiratory Medicine (711 citations) and Immunology (435 citations). Chen Yang has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Xiangmin Tong, Zhongkai Gu, Xiaolong Liu, Wei Chen, Xiaomo Wu, Zhi‐Ming Shao, Yanchun Li, Yi Zhou, Jing Du and Xueying Ren. Their work appears in journals such as Breast Cancer Research and Treatment, Cell Death and Disease, Cancer Cell International, Aging and Biomedicine & Pharmacotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.